CYP19A1 and breast carcinoma: The body of laboratory work from the Northwestern Tamoxifen Team was confirmed in patients, half a decade later, by Dr. Mat Ellis [156] using high- and low-dose estrogen to provide clinical benefit for breast cancer patients who recurred during aromatase inhibitor treatment.